#AmericanDiabetesAssociation #diabetes #sulfonylureas #glipizide
84th Scientific Sessions of the American Diabetes Association in Orlando, Florida. This conference, held from June 21 to June 24, 2024, featured significant discussions on diabetes management.
One of the key highlights was from a session titled "Sulfonylureas in Type 2 Diabetes Management: Should They Stay or Should They Go?". Dr. Elbert S. Huang, a prominent expert in the field, emphasized the critical role of sulfonylureas in diabetes treatment. He remarked, "Considering the broader population, sulfonylureas are essential in formularies as many T2DM patients might otherwise go untreated. With the resources needed to treat one patient with GLP-1 receptor agonists, we could treat 177 patients with sulfonylureas." This comment is particularly relevant for resource-limited settings.
Dr. Elbert Huang emphasized the careful selection of sulfonylureas to minimize risks, especially hypoglycemia. He specifically recommended short-acting variants like glipizide which offer effective glucose control at much lower costs compared to alternatives such as insulin, GLP-1 receptor agonists, and SGLT2 inhibitors. Furthermore, he advised prescribing the lowest effective dose and adjusting it based on each patient’s meal size and activity level to optimize treatment outcomes for Type 2 diabetes.
Stay tuned as we continue to bring you more updates and expert insights from the ADA sessions, shaping the future of diabetes management across the globe.
ADA supports Improving Awareness on diabetes, availability and acceSs to High quality Affordable medications for better health outcomes in countries like India.
Citations:
ADA 2024, Scientific Sessions, Dr. Elbert Huang, "Sulfonylureas in T2DM Management, Should They Stay or Should They Go?", June 21-24, 2024.